Compass Therapeutics Inc Stock Price, News & Analysis

Compass Therapeutics (Nasdaq: CMPX) presented preclinical data on CTX-10726, a tetravalent bispecific antibody targeting PD-1 and VEGF-A, at the 40th SITC Annual Meeting on November 7, 2025.

Key findings: CTX-10726 showed high-affinity binding to human and cynomolgus VEGF-A and PD-1, dose-dependent blockade of VEGF-A/VEGFR2 and PD-1/PD-L1 interactions, and potent IFN-γ immunomodulatory activity in vitro. In vivo, CTX-10726 produced tumor elimination in multiple models and demonstrated superior anti-tumor activity versus comparator antibodies including ivonescimab and bevacizumab in xenograft and knock-in mouse models. The company said an IND submission is on track for Q4 2025. Presentation materials will be posted on the company website after the meeting.

Compass Therapeutics (Nasdaq: CMPX) will participate in three investor events in November 2025: Guggenheim Healthcare Innovation Conference in Boston on Nov 10, 2025 at 3:30 PM ET, Stifel 2025 Healthcare Conference in New York on Nov 12, 2025 at 4:00 PM ET, and Jefferies Global Healthcare Conference in London on Nov 20, 2025 at 12:00 PM GMT.

Each presentation will be webcast; links are provided and presentations will be archived for 90 days on Compass’ Events page for replay.

Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology biopharmaceutical company, has announced its participation in four major investor conferences in September 2025:

• Citi's Biopharma Back to School Conference in Boston (Sept 2)
• Cantor Global Healthcare Conference in New York (Sept 3, 2:10 PM ET)
• H.C. Wainwright Global Investment Conference in New York (Sept 8, 11 AM ET)
• Morgan Stanley Global Healthcare Conference in New York (Sept 9, 5:35 PM ET)

All presentations will be archived for 90 days on Compass' Events page.

Compass Therapeutics (NASDAQ: CMPX), a clinical-stage oncology biopharmaceutical company, has announced the pricing of an upsized public offering totaling $120 million. The offering consists of 33,290,000 shares of common stock priced at $3.00 per share and pre-funded warrants to purchase 6,710,000 shares at $2.9999 per warrant.

The underwriters have a 30-day option to purchase up to 6 million additional shares. The offering is expected to close around August 14, 2025. The company plans to use the proceeds for commercial readiness preparations, research and clinical development of product candidates, and general corporate purposes.

Compass Therapeutics (NASDAQ: CMPX), a clinical-stage oncology biopharmaceutical company, has announced a proposed public offering of common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase additional shares under the same terms.

The company plans to use the proceeds for commercial readiness preparations, research and clinical development of its product candidates, and general corporate purposes. Jefferies, Piper Sandler, and Guggenheim Securities are serving as joint active bookrunning managers for the offering.

The offering will be conducted through a shelf registration statement on Form S-3 that was declared effective by the SEC on September 6, 2024.

Compass Therapeutics (NASDAQ:CMPX) reported Q2 2025 financial results and provided updates on its oncology pipeline. The company reported a net loss of $19.9 million ($0.14 per share), compared to $13.1 million in Q2 2024. Key highlights include promising survival data for tovecimig in biliary tract cancer, with secondary endpoint analysis now expected in Q1 2026.

In the CTX-8371 Phase 1 trial, two significant partial responses were observed in post-checkpoint inhibitor settings, including 100% tumor reduction in a lung cancer patient and >90% reduction in a breast cancer patient. The company's new drug CTX-10726 showed superior results compared to ivonescimab in preclinical studies.

Compass ended Q2 with $101 million in cash, providing runway into 2027. R&D expenses increased 47% year-over-year to $16.4 million, primarily due to manufacturing costs for tovecimig and CTX-10726.

Compass Therapeutics (NASDAQ: CMPX), a clinical-stage oncology biopharmaceutical company, will host its Q2 2025 financial results conference call on August 11, 2025, at 8:00 AM ET. The presentation will include updates on multiple programs including the tovecimig Phase 2/3 study, clinical data for CTX-8371, and preclinical data for CTX-10726.

Investors can access the webcast via the provided link or join by phone using the dial-in numbers. A replay will be available for 90 days on Compass' Events page.

Compass Therapeutics (NASDAQ: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapeutics, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company will engage in a fireside chat scheduled for June 5, 2025, from 11:05 to 11:35 AM ET. The presentation will be accessible via webcast and will remain available for replay on Compass' Events page for 90 days following the event.

Compass Therapeutics (NASDAQ: CMPX) reported significant progress in Q1 2025, highlighted by tovecimig meeting its primary endpoint in the Phase 2/3 COMPANION-002 study for biliary tract cancer (BTC). The drug achieved a 17.1% overall response rate compared to 5.3% for paclitaxel alone. The company also advanced other pipeline candidates, including CTX-10726 (PD-1 x VEGF-A bispecific antibody) and CTX-8371.

Financial results showed a net loss of $16.6 million ($0.12 per share) compared to $10.8 million in Q1 2024. R&D expenses increased 37% to $13.1 million, while G&A expenses rose 51% to $4.9 million. The company maintains a strong financial position with $113 million in cash, providing runway into 2027.